Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > GSK Begins Late-Stage Mepolizumab Trials in Severe Asthma

Drug Industry Daily

Oct. 31, 2012 | Vol. 11 No. 214

GSK Begins Late-Stage Mepolizumab Trials in Severe Asthma

GlaxoSmithKline (GSK) is moving its biologic mepolizumab forward, beginning two Phase III trials of the drug as an adjunct therapy in severe uncontrolled refractory asthma.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Pfizer Halts Phase III Trial of Lyphoma Drug After Interim Analysis House Committee Probes FDA Official’s Departure Briefs Actavis Buys Warner Chilcott In $8.5B All Stock Purchase

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.